• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Leap Therapeutics Inc.

    4/25/25 8:54:12 PM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LPTX alert in real time by email
    DEFA14A 1 tm252386d4_defa14a.htm DEFA14A tm252386-2_nonfiling - none - 7.7031597s
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934 (Amendment No.      )
    Filed by the Registrant ☒
    Filed by a Party other than the Registrant ☐
    Check the appropriate box:
    ☐
    Preliminary Proxy Statement
    ​
    ☐
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ​
    ☐
    Definitive Proxy Statement
    ​
    ☒
    Definitive Additional Materials
    ​
    ☐
    Soliciting Material under §240.14a-12
    ​
    LEAP THERAPEUTICS, INC.
    ​
    (Name of Registrant as Specified In Its Charter)​
     
    ​
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)​
    Payment of Filing Fee (Check all boxes that apply):
    ☒
    No fee required.
    ​
    ☐
    Fee paid previously with preliminary materials.
    ​
    ☐
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
    ​

    GRAPHIC

    You May Vote Your Proxy When You View The Material On The Internet. You Will Be Asked To Follow The Prompts To Vote Your Shares. LEAP THERAPEUTICS, Inc. 47 Thorndike Street, Suite B1-1 Cambridge, MA 02141 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS to be held on June 18, 2025 Dear Shareholder, The 2025 Annual Meeting of Shareholders of Leap Therapeutics, Inc. will be conducted virtually over the Internet on June 18, 2025, at 11:30 AM (local time). Proposals to be considered at the Annual Meeting: (1) To consider and act upon a proposal to elect to the Company’s Board of Directors three persons nominated by the Board of Directors; (2) To consider and act upon, by a non-binding advisory vote, a resolution to approve the compensation of our named executive officers; and (3) To consider and act upon a proposal to ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the 2025 fiscal year; ending December 31, 2025. The Board of Directors recommends a vote “FOR” all nominees under Proposal 1, and “FOR” Proposals 2 and 3. . Your electronic vote authorizes the named proxies to vote your shares in the same manner as if you marked, signed, dated, and returned the proxy card. The Proxy Materials are available for review at: https://www.cstproxy.com/leaptx/2025 CONTROL NUMBER LEAP THERAPEUTICS, INC. c/o Continental Proxy Services 1 State Street, New York NY 10004 197046 Leap Therapeutics Proxy Notice Rev1 Front Vote Your Proxy on the Internet: https://www.cstproxyvote.com Have your notice available when you access the above website. Follow the prompts to vote your shares. Vote during the Meeting – If you plan to attend the virtual online annual meeting, you will need your 12 digit control number to vote electronically during the annual meeting. To attend the annual meeting, visit: https://www.cstproxy.com/leaptx/2025 MOBILE VOTING On your Smartphone/Tablet, open the QR Reader and scan the below image. Once the voting site is displayed, enter your Control Number from the proxy card and vote your shares.

    GRAPHIC

    LEAP THERAPEUTICS, Inc.. 47 Thorndike Street, Suite B1-1 Cambridge, MA 02141 Important Notice Regarding the Availability of Proxy Materials For the 2025 Annual Meeting of Shareholders to be Held On June 18, 2025 The following Proxy Materials are available to you to review at: https://www.cstproxy.com/leaptx/2025 - the Company’s Annual Report for the year ended December 31, 2024. - the Company’s 2025 Proxy Statement. - the Proxy Card. - any amendments to the foregoing materials that are required to be furnished to shareholders. This is not a ballot. You cannot use this notice to vote your shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. If you would like to receive a paper or e-mail copy of these documents, you must request one. There is no charge for such documents to be mailed to you. Please make your request for a copy as instructed below on or before June 4, 2025 to facilitate a timely delivery. You may also request that you receive paper copies of all future proxy materials from the Company. ACCESSING YOUR PROXY MATERIALS ONLINE Have this notice available when you request a paper copy of the proxy materials or to vote your proxy electronically. You must reference your Control number. REQUESTING A PAPER COPY OF THE PROXY MATERIALS By telephone please call 1-888-266-6791, or By logging on to https://www.cstproxy.com/leaptx/2025 or By email at: [email protected] Please Inc.lude the company name and your control number in the subject line. 197046 Leap Therapeutics Proxy Notice Rev1 Back

    Get the next $LPTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LPTX

    DatePrice TargetRatingAnalyst
    1/29/2025Buy → Neutral
    H.C. Wainwright
    1/29/2025$9.00 → $1.25Outperform → Neutral
    Robert W. Baird
    6/28/2024$8.00Buy
    Rodman & Renshaw
    10/4/2021$6.00Buy
    Mizuho
    9/14/2021$3.00 → $4.00Outperform
    Raymond James
    More analyst ratings

    $LPTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Leap Therapeutics Reports First Quarter 2025 Financial Results

      CAMBRIDGE, Mass., May 13, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter of 2025. Leap Highlights: Reported positive data from the randomized, controlled Part B of the Phase 2 DeFianCe study of sirexatamab (DKN-01) plus bevacizumab and chemotherapy in second-line colorectal cancer (CRC) patients demonstrating significantly higher overall response rate (ORR) and longer progression-free survival (PFS) across DKK1-high and VEGF-naïve subgroupsHosted virtual key opinion leader (KOL) event featuring Zev A. Wainberg, MD, to further discuss the

      5/13/25 7:00:00 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Purple Biotech Appoints Shai Lankry as Chief Financial Officer

      U.S.-based Lankry brings over 20 years of financial leadership in biotech and healthcare with a proven track record of driving strategic growth, operational excellence, and capital market execution, including leading a U.S. IPO and M&A transaction REHOVOT, Israel, May 12, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, announced today the appointment of Shai Lankry as its Chief Financial Officer. "We are pleased to welcome Shai on board. His extensive experience in the U.S. and European biotech and pharma marke

      5/12/25 7:30:00 AM ET
      $GMDA
      $LPTX
      $PPBT
      $WST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical/Dental Instruments
    • Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting

      FL-501 fully restored body composition and reversed key indicators of cachexia in preclinical models Findings confirm GDF-15's role in cachexia and support advancing FL-501 into the clinic CAMBRIDGE, Mass., April 25, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will present preclinical data of FL-501 in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting taking place April 25-30 in Chicago, Illinois. FL-501 is a potential best-in-class monoclonal antibody targeting growth differentiation factor 15 (GDF-15), a cytokine that is impli

      4/25/25 1:00:00 PM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LPTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Leap Therapeutics Inc.

      SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)

      11/14/24 6:07:56 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Leap Therapeutics Inc.

      SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)

      4/25/24 8:39:23 PM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Leap Therapeutics Inc.

      SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)

      4/19/24 4:31:26 PM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LPTX
    Financials

    Live finance-specific insights

    See more
    • Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

      Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024. Leap Highlights: Reported positive updated data from Part B of the Phase 2 DeFianCe study of sirexatamab (DKN-01) in second-line patients with advanced microsatellite stable (MSS) colorectal cancer (CRC) confirming:Statistically significant 32% higher overall response rate (ORR), 3.5 month longer progression-free survival (P

      3/26/25 7:05:00 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

      Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFS in second-line CRC patients with high DKK1 levels treated with sirexatamab plus bevacizumab and chemotherapy Statistically significant 22% higher ORR and 2.6 month longer PFSin patients who had not had prior anti-VEGF therapy Leap to host a conference call to present clinical data today, March 26, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today presented updated preliminary data from Part B of the DeFianCe study (NCT05480306), a Phase 2, open-label, g

      3/26/25 7:00:00 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

      35% objective response rate (ORR) in second-line colorectal cancer (CRC) patients treated with sirexatamab (DKN-01) plus bevacizumab and chemotherapy, compared to 23% ORR in the control arm DKK1 levels highly correlated with clinical activity in CRC population ORR benefit with sirexatamab observed across multiple potential Phase 3 CRC populations Preparations will begin for a registrational Phase 3 study in second-line CRC patients DisTinGuish Part C study in gastric cancer demonstrates activity in biomarker populations, but not the signal necessary to advance into Phase 3 Leap to host a conference call to present clinical data today, January 28, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass., Jan.

      1/28/25 7:00:00 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LPTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leap Therapeutics downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Leap Therapeutics from Buy to Neutral

      1/29/25 7:15:39 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leap Therapeutics downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Leap Therapeutics from Outperform to Neutral and set a new price target of $1.25 from $9.00 previously

      1/29/25 7:15:19 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rodman & Renshaw initiated coverage on Leap Therapeutics with a new price target

      Rodman & Renshaw initiated coverage of Leap Therapeutics with a rating of Buy and set a new price target of $8.00

      6/28/24 8:18:39 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LPTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO,CFO,Pres.,GC,Treas.&Sec. Onsi Douglas E converted options into 32,500 shares, increasing direct ownership by 44% to 106,146 units (SEC Form 4)

      4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)

      4/1/25 9:55:11 PM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP, Head of Reg Affairs/Qual Granfield Christine converted options into 22,500 shares and covered exercise/tax liability with 6,604 shares (SEC Form 4)

      4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)

      4/1/25 9:54:08 PM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Baum Jason covered exercise/tax liability with 6,604 shares and converted options into 22,500 shares (SEC Form 4)

      4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)

      4/1/25 9:53:26 PM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LPTX
    SEC Filings

    See more
    • Leap Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - LEAP THERAPEUTICS, INC. (0001509745) (Filer)

      5/13/25 7:10:27 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Leap Therapeutics Inc.

      10-Q - LEAP THERAPEUTICS, INC. (0001509745) (Filer)

      5/13/25 6:51:44 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Leap Therapeutics Inc.

      DEFA14A - LEAP THERAPEUTICS, INC. (0001509745) (Filer)

      4/25/25 8:54:12 PM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LPTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors

      CAMBRIDGE, Mass., Sept. 6, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused  on developing targeted and immuno-oncology therapeutics, today announced the appointment of Richard L. Schilsky, MD, FASCO, FACP, FSCT to its Board of Directors, effective September 1, 2022. Dr. Schilsky brings over 40 years of experience in medicine and clinical research, specializing in new drug development and clinical trials for a wide range of cancers. "We are honored to welcome Dr. Schilsky, who brings a wealth of experience and deep knowledge to bolster Leap's drug development strategy," said Christopher Mirabelli, PhD, Chairman of Leap Therapeutics' Board. "He is a

      9/6/22 7:00:00 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care